Introduction
1 Although plasma transfusions are frequently prescribed worldwide, the indications for 2 their use remain unclear. In 2011, 3,882,000 plasma units were transfused in the 3 United States in adults and children (1) . According to US pediatric health information 4 administrative databases, nearly 3% of all recorded pediatric admissions receive a 5 plasma transfusion during their hospital stay (2). In France, administration of plasma 6 has increased by more than 40% over the last ten years, often in clinical situations 7
where the biological and/or clinical criteria do not seem to justify its use (3) . Experts 8 recommend plasma transfusions mainly in the context of massive transfusion and in 9 case of bleeding associated with documented abnormal coagulation tests (4, 5) . 10 11 In massively bleeding patients, observational data suggest that early use of plasma 12 and platelets seems to be associated with improved outcomes in patients with life-13 threatening bleeding (6) . However, in a less critical clinical context, adult and 14 pediatric epidemiological studies have shown an independent association between 15 plasma transfusion and development of nosocomial infections (7, 8) , acute 16 respiratory distress syndrome (9) (10) (11) , multiple organ failure (8, 11) and mortality (12) . 17 Therefore, it might seem important to determine when the benefits outweigh the side 18 effects, especially as previous studies have already shown that plasma transfusions 19 failed to correct mildly abnormal coagulation tests (13) (14) (15) . There is no specific 20 pediatric data on this issue. However, the increased morbidity associated with 21 plasma transfusions in observational studies might be due to unrecognized biases, 22
as plasma might be given to sicker patients. 23 24 Plasma transfusions are frequently administered to correct abnormal coagulation 25 tests (16) which are often viewed as predicting a risk of bleeding although Segal et al 26 3 have shown that abnormal coagulation tests are not associated with increased risk of 1 bleeding in most procedures (17) . In 2007, Lauzier et al reported that plasma 2 transfusions were often administered to critically ill adults who were not bleeding and 3 who did not required an invasive procedure/surgery (18) . In 2011, Stanworth et al 4 reported that half of the plasma transfused in the UK was given to non-bleeding 5 patients (15) .These practices are not in accordance with the guidelines for the use of 6 frozen plasma published by expert committees (4, 5) . This might lead to a significant 7 waste, especially as blood availability is already a major concern. 8 9
There are few published reports of the reasons for plasma transfusion in children. A 10 recent pediatric international survey showed an important heterogeneity in plasma 11 transfusion thresholds and strategies (19), with two-thirds of responding pediatric 12 critical care physicians stating that they prescribe plasma transfusions for non-13 bleeding critically ill children. This marked heterogeneity in plasma transfusion 14 patterns might be due to the absence of randomized controlled trials (RCTs) that 15 could guide plasma transfusion strategies (20) . 16 17 This point-prevalence study is part of a larger undertaking that aims to design a RCT 18 to address optimal plasma transfusion strategies in critically ill children (8, 19, 20) . 19
Our primary objectives were to identify the characteristics and clinical situations 20 resulting in plasma transfusion and to evaluate changes in coagulation laboratory 21 values resulting from the initial plasma transfusion in critically ill children. 22
23

Methods
24
Study sites and population 25 4 This point-prevalence study is an international multicenter cross-sectional 1 observational study carried out in 101 Pediatric Intensive Care Units (PICUs) in 21 2 countries. Clinical sites were recruited through several research networks including 3
BloodNet of the Pediatric Acute Lung Injury and Sepsis Investigators Network 4 (PALISI), the Canadian Critical Care Trials Group (CCCTG), the European Society of 5 Pediatric Neonatal Intensive Care (ESPNIC), the UK Pediatric Intensive Care Society 6 (PICS), the Groupe Francophone de Réanimation et Urgences Pédiatriques 7 (GFRUP), and the Australian and New Zealand Intensive Care Society (ANZICS), as 8 well as through personal contacts made by the study investigators. For each study 9 site, six one-week periods were randomly predefined over six consecutive months 10 (April to September 2014). Within each week, screening was done and data were 11 collected on 5 days (Monday to Friday, from midnight to midnight). 12
All critically ill children aged 3 days to 16 years old admitted to a participating PICU 13 on one of the 30 study days were considered eligible. Any eligible patient for whom at 14 least one plasma transfusion was administered on any study day was included 15 unless one of the exclusion criteria (i.e. plasmapheresis and gestational age less 16 than 37 weeks at the time of PICU admission) was present. If a patient was 17 readmitted within 24 hours of PICU discharge, this was considered part of the same 18 admission. 19 20
Outcome definitions 21
The primary outcome was the primary indication for the first plasma transfusion and 22 the coagulation tests prior to that transfusion. We only considered plasma 23 transfusions, but not cryoprecipitate, albumin, or infusions of specific coagulation 24
factors. 25
Clinical indications were categorized as follows: 26 5 A) Critical bleeding: massive bleeding (transfusion of all blood products > 80 1 ml/kg within 24 hours), bleeding in specific sites (intra-cranial, intra-ocular, 2 retroperitoneal, intra-spinal, pericardial, non-traumatic intra-articular);or 3 bleeding requiring a surgical intervention or drainage (e.g. hemothorax 4 requiring drainage) (21) The secondary outcome was the changes in coagulation tests that occurred after the 13 first plasma transfusion. 14 We also collected data on the transfusion itself, such as the product that had been 15 used [Fresh-Frozen Plasma (FFP), Frozen Plasma (FP), Mirasol-treated Plasma, 16
Solvent/Detergent Plasma (SD plasma)] (22) , the rate and volume of the transfusion. 17
Description and clinical outcome of the population was studied using daily Pediatric 18 Logistic Organ Dysfunction (PELOD)-2 score (23), length of mechanical ventilation, 19 PICU length of stay, and PICU mortality. Because the PELOD-2 score is predictive of 20 mortality when measured on certain specific days, we collected patient data on days1 21 (first transfusion), 2, 5, 8, and 12 of PICU stay (24) . Length of mechanical ventilation, 22 PICU length of stay, and PICU mortality were censored 28 days after the end of the 23 enrollment period. 24
25
Ethics approval 26 6 This study was approved by ethics committees or boards at all sites. Five centers 1 (two in Canada, one in Denmark, Italy and Norway) required to obtain individual 2 patient written consent. French and Belgian sites provided study information in the 3 PICU waiting room, with an opt-out (or passive) consent. The ethics committees or 4 boards of all other sites did not require individual consent. 5 6
Sample size 7
The sample size was calculated to attain a precision of ± 5% of the proportion of 8 patients in whom plasma was transfused despite the fact they were non-bleeding and 9
without planned invasive procedures. The estimated proportion was 34%, based on 10 previously reported data in critically ill adults (18). Based on these assumptions, the 11 study aimed to enroll 339 critically ill children who received at least one plasma 12 transfusion. 13
14
Statistical analysis 15
Descriptive statistics are reported as mean ± standard deviation (SD), median and 16 interquartile range (IQR), or proportions with their 95%CI. 17
We assessed the association between the indication for plasma transfusion and the 18 different variables (demographic data, coagulation tests, clinical outcome measures) 19 with a Pearson Chi-Square test (for dichotomous variables) and a one-way ANOVA 20 test for continuous variables. We assessed the difference between coagulation test 21 results drawn before and after plasma transfusion using the Wilcoxon signed rank 22 test. Coagulation test cut-offs were determined incrementally, using the Wilcoxon 23 signed rank test, by steps of 0.5 and 5 for International Normalized Ratio (INR) and 24 activated partial thromboplastin time (aPTT), respectively. We also assessed the 25 association between plasma transfusion dose and change in coagulation tests using 26 
Results
7
Frequency and description of the population 8
One hundred and one PICUs from 21 countries participated in this study, from April 9
to September 2014. Fifty-six centers were in Europe, 35 in North America, 5 in 10 Oceania, 3 in Asia, and 2 in South America. The median number of beds per PICU 11 was [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . 12
Over the 30 study days, 13,192 patients were admitted and hence eligible. Per PICU, 13 the median number of patients already admitted at the beginning of a study week 14 was 9 (IQR 5-13) and the median number of new admissions on each study day was 15 2 (IQR 1-3). 16
Only one patient was not enrolled because written consent was not obtained. Plasma 17 transfusions were observed in 443 patients (3.4%, 95%CI 3.1-3.7). The median 18 length of PICU stay prior to the first plasma transfusion was 1 day (IQR 0-5). 19 Table 1 describes the baseline characteristics of included patients. The median age 20 and weight were 1 year (IQR 0.2-6.4) and 9.1 kg (IQR 4.0-21.0), respectively. 43% 21 were males. The median PELOD-2 score was 7 (IQR 5-10). 22
The center which included the largest number of patients contributed 11.1% of the 23 results. Fifteen centers (15/101, 14 .8%) did not transfuse plasma during their six 24 study weeks. 25 
Indications for plasma transfusion 1
The primary indication for plasma transfusion was critical bleeding in 22.3% of 2 patients (95%CI 18.7-26.5), minor bleeding in , planned 3 surgery or procedure in 11.7% (95%CI 9.1-15.7), and high risk of post-operative 4 bleeding in 10.6% (95%CI 8.0-14.0). No bleeding or planned procedures were 5 reported in 34.1% of patients (95%CI 29.8-38.6) ( Fig.1) . Among the latter, 68.3% 6 (95%CI 60.4-75.1) were transfused to correct abnormal coagulation tests, were considered at high risk of bleeding due to their medical 8 condition, 12.6% (95%CI 8.2-18.8) were transfused to treat hypovolemia, and 6.0% 9 (95%CI 3.2-10.9) were transfused to replace losses (ascites, chylothorax or 10 antithrombin deficiency). 11
Forty-eight patients received plasma while on Extracorporeal Life Support (ECLS); 12 12 of these (25%) received plasma for critical bleeding. Six (13%) received plasma as 13 part of an ongoing trial (NCT01903863). 14 15 Coagulation tests before plasma transfusion 16
Coagulation tests were performed prior to the first plasma transfusion in 96.4% of the 17 patients. Prothrombin Time (PT) was measured in seconds and in percentage in 18 59.1% and 23.3% of the patients, respectively. INR and aPTT were measured in 19 74.0% and 90.3% of patients, respectively. The median time between sampling for 20 coagulation tests and initiation of plasma transfusion was 3.5 hours (IQR 1.7-6.5). 21
The median results for INR and aPTT were 1.5 (IQR 1.3-2.0) and 48 (IQR 36-75), 22
respectively. Thirty percent of patients transfused were not bleeding, had no planned 23 procedure, and had an INR < 1. 5. 24 Thromboelastography (TEG) was performed in seven centers (located in three 25 countries: Denmark, United Kingdom and USA) on 13 (2.9%) patients. Rotational 26 9 Thromboelastometry (ROTEM) was performed in four centers (located in Belgium, 1 France, Italy, and Switzerland) on 7 (1.6%). 2 3
Plasma transfusions 4
At the time of the first plasma transfusion, Fresh-Frozen Plasma was given to 75% of 5 the patients, whereas Solvent/Detergent Plasma and Frozen Plasma were given in 6 14% and 6%, respectively. Physicians were not aware of the type of plasma in 5% of 7 transfusions. The median dose of plasma was 11 ml/kg (IQR 9.7-15.1). Plasma was 8 transfused over a median time of 60 minutes (IQR 30-104). The median dose and 9 median transfusion rate were not significantly higher for patients with critical bleeding 10 (p=0.10). 11
12
Coagulation tests after plasma transfusion 13
Coagulation tests were performed after the first plasma transfusion in 89.4% of 14 patients. The median time between the end of the plasma transfusion and sampling 15 for coagulation tests was 4.0 hours (IQR 1.7-8.2). 16
The median results for INR and aPTT were 1.4 (IQR 1.2-1.7) and 41 (IQR 33-59), 17
respectively. The median INR and aPTT changes are -0.2 (IQR -0.4 to 0, n=281, 18 p<0.001) and -5 (IQR -17 to 2, n=356, p<0.001), respectively (Fig. 2) . 19
After plasma transfusions, TEG and ROTEM were performed in 7 (1.6%) and 4 20 (0.9%) patients, respectively. Median length of mechanical ventilation was 5 days (IQR 1-16) and median PICU 10 length of stay was 10 days (IQR 4-24) in our study population. Table 2 shows that 11 there were no statistically significant variations according to the primary indication for 12 plasma transfusion. PICU mortality was 26.9% (119/443, 95%CI 23-31). 13
14
Discussion
15
In this large international observational study, we examined the indications of plasma 16 transfusions in critically ill children and their effects on coagulation tests. We found 17 that 34% of patients who receive plasma were neither bleeding nor being prepared 18 for a procedure, whereas only 22% receive plasma for critical bleeding. 19 Clinically significant decrease in INR and aPTT values were only noted for INR 20 values > 2.5 or aPTT values > 60 sec. These findings underscore that when the INR 21 is only mildly prolonged, the assay is not sensitive to the increase in coagulation 22 factors resulting from transfusion. It must be recognized that coagulation tests may 23 not be the most appropriate measure of plasma transfusion efficacy, as they fail to 24 predict bleeding (17) . Unfortunately, alternative laboratory measures to better 25 ascertain this do not exist at the present time. adults was to «prepare» a patient with an elevated INR for invasive procedures (16) . 3
In 2007, Lauzier et al also showed that plasma transfusions were often administered 4 to critically ill adults who were not bleeding; 33.7% of plasma orders were for non-5 bleeding patients with no planned invasive procedures (18). Our study shows very 6 similar results; 34.1% of patients transfused with plasma were not bleeding and had 7 no planned invasive procedures. 8 9 The effect of plasma transfusions on coagulation tests has been described in adults. 10
In 121 patients with moderately abnormal coagulation tests (INR < 1.85), the post-11 transfusion INR value decreased to below 1.1 in only 0.8% of this mixed surgical and 12 medical intensive care patient population (13) . In another study, Holland et al showed 13
that plasma transfusion did not correct INR levels < 2.0-2.5 in 103 adult patients who 14 received 174 transfusions (14). These studies demonstrate the inability of the INR to 15 document the effect of plasma infusions at INR values commonly encountered in 16 critical care patients. Similar results have also been reported by Stanworth et al (15) . 17
Our study shows that only severely abnormal coagulation tests are improved by 18 plasma transfusions and that this association was non-linear. This is likely due to the 19 exponential relationship between coagulation factor concentration and coagulation 20 test results (25). Our results suggest that a mild to moderate elevation of the INR in a 21 non-bleeding patient is not a worthwhile target for intervention. 22
23
Despite improvements in the management of blood products, some modeling 24
suggests that blood availability could become a major concern in the next 5-10 years 25 due to increasing demand in certain patient populations (26) which in turn justifies the 26 Page 13 of 32 AJRCCM Articles in Press. Published on 10-April-2015 as 10.1164/rccm.201503-0450OC Copyright © 2015 by the American Thoracic Society rationalization of blood product (including plasma) transfusions. More specifically, in 1 order to ensure the best use of blood products and to reduce unnecessary 2 transfusion, it is important to ascertain whether transfusing critically ill but non-3 bleeding patients with a baseline INR < 2.5 is appropriate. Indeed, it is possible that 4 there are some benefits, which are not measured by coagulation tests. Furthermore, 5 these cut-offs are based on observational data, and might not truly reflect the efficacy 6 of plasma transfusions, which could only be tested in a randomized controlled trial. 7
Nonetheless, it seems obvious that a more restrictive transfusion strategy could 8 considerably reduce the unnecessary use of plasma, which would allow for more 9 appropriate resource utilization where truly needed. 10 11 This is the largest prospective observational study on plasma transfusions in critically 12 ill children, both in terms of number of patients and in terms of PICUs. Worldwide 13 enrollment enhances external validity. This study also avoided selection bias, as all 14 but one eligible patients were enrolled. Definitive conclusions cannot be drawn but 15 meaningful hypotheses have been generated. Our findings reveal certain very 16 striking observations that suggest overuse of plasma in certain clinical contexts. The 17 data will allow us to design a future RCT to evaluate these hypotheses. 18 19 Some limitations must be recognized. The design of our study does not permit 20 comparison between patients transfused and not transfused with plasma. This was 21 not the purpose of our study as data collection was limited only to patients who 22 received plasma (prevalent cases) and not to the much larger group of patients who 23 did not receive plasma. The patients in our study were sicker than those in a general 24 PICU population, as our median PELOD-2 score and mortality rate were 7 (IQR 5-10) 25 and 26.6%, respectively, compared to 4 (2-7) and 6.0% in a large PICU population 26 (23) . This may reflect the fact that plasma was given mainly to sicker patients. 1
Although we enrolled virtually all patients admitted in the participating PICUs, there 2 might have been a selection bias for centers themselves, as some sites with specific 3 transfusion strategies might have been less keen to participate. The limited data 4 collected did not include information on co-interventions, such as heparin, 5 antithrombin, coagulation factor concentrates, vitamin K, or platelet administration. 6
Finally, mortality was higher than anticipated in our patient cohort. It is therefore 7 possible we underestimated the burden of rapidly fatal disease, as we did not 8 measure ventilator-free days but only the length of mechanical ventilation. 9
10 This international observational study shows that non-bleeding patients represent 11 more than half of the critically ill children receiving plasma transfusions. 
